| US 7,579,370 B2 | ||
| Fused heterocycles | ||
| Michele L. R. Heffernan, Worcester, Mass. (US); James M. Dorsey, Durham, N.C. (US); Qun Kevin Fang, Wellesley, Mass. (US); Robert J. Foglesong, Durham, N.C. (US); Seth C. Hopkins, Clinton, Mass. (US); Cyprian O. Ogbu, Durham, N.C. (US); Mustapha Soukri, Raleigh, N.C. (US); and Kerry L. Spear, Concord, Mass. (US) | ||
| Assigned to Sepracor Inc., Marlborough, Mass. (US) | ||
| Filed on Aug. 03, 2007, as Appl. No. 11/833,903. | ||
| Application 11/833903 is a continuation in part of application No. 11/825093, filed on Jul. 02, 2007. | ||
| Claims priority of provisional application 60/806391, filed on Jun. 30, 2006. | ||
| Claims priority of provisional application 60/842465, filed on Sep. 05, 2006. | ||
| Claims priority of provisional application 60/914293, filed on Apr. 26, 2007. | ||
| Prior Publication US 2008/0004328 A1, Jan. 03, 2008 | ||
| Int. Cl. A61K 31/40 (2006.01); A61K 31/34 (2006.01); A61K 31/19 (2006.01); A01N 43/38 (2006.01); A01N 43/08 (2006.01); A01N 37/00 (2006.01) | ||
| U.S. Cl. 514—412 [514/469; 514/414; 514/557] | 15 Claims |
1. A pharmaceutical composition in an oral unit dosage form comprising, per dosage unit, a pharmaceutically acceptable carrier
and a daily dosage of a compound in an amount of about 0.1 mg to about 7000 mg, said compound having the formula:
 R1 is a member selected from the group consisting of H, and substituted or unsubstituted arylalky;
R2 is a member selected from the group consisting of H, and substituted or unsubstituted arylalky; and
R4 is a member selected from OH and O−X+
wherein
X+ is a positive ion which is a member selected from organic positive ions and inorganic positive ions,
wherein
substituted or unsubstituted arylalkyl has the formula:
 in which
Ar is substituted or unsubstituted aryl; and
n is an integer from 1 to 4.
|